| |
Cell therapy developers face many challenges as they transition from benchtop to bedside.Here we examine when and how to consider transitioning from research-use-only to animal-free (AF) and GMP critical reagents. Download now.
|
|
Today’s Big NewsJul 10, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
| By Darren Incorvaia,Gabrielle Masson Just as there’s been little relief from the intense heat scorching much of the world this summer, the biotech industry continues to be burned by layoffs. According to the Fierce Biotech Layoff Tracker, there were 38 layoff announcements in the second quarter of 2024, compared to 36 in the same period during 2023. |
|
|
|
By Angus Liu Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma commercial team. And the division’s newly named commercial chief Christine Roth is among those changes. |
By Conor Hale Medtronic’s July 9 recall covers all versions and lots of its NIM Standard and NIM Contact EMG reinforced endotracheal tubes used during surgery. |
By Nick Paul Taylor Roche has claimed the top spot in a ranking of the online presence of drugmakers, climbing two spots on the strength of its provision of local websites and industry-leading use of LinkedIn. |
|
Dive into the cutting-edge world of recombinant antibody engineering, from optimizing your antibody plasmid to antibody maturation and humanization. Explore innovative techniques and strategies that enhance antibody efficacy, paving the way for breakthroughs in therapeutic development. Download now.
|
|
By James Waldron Flagship Pioneering has brought in $2.6 billion via its eighth venture fund, with a further $1 billion coming from an array of side funds, as the venture creation firm hunts for even more Big Pharma partnerships. |
By Angus Liu After a meeting with the FDA last week, Elevar Therapeutics and Jiangsu Hengrui Pharma are preparing to refile their PD-1 combination potentially as early as October, Elevar’s CEO Saeho Chong, Ph.D., said. |
By Kevin Dunleavy Just seven weeks after projecting an 18% revenue boost for this year, Indivior has slashed its estimate to an 8% increase, citing competitive pressures for its opioid addiction treatment Sublocade and “payor dynamics” for its schizophrenia drug Perseris. |
By Annalee Armstrong Amylyx’s co-CEOs Josh Cohen and Justin Klee have already had to make what may end up being the toughest decision of their careers. Next up, they're rebuilding the pipeline. |
By Conor Hale Despite letting go of Grail, Illumina isn’t shying away from M&A. It acquired the single-cell analysis startup Fluent BioSciences with cash on hand. |
By Andrea Park U.K.-based comms giant WPP has been selected as one of the primary networks serving global advertising efforts for AstraZeneca’s oncology business. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of “Podnosis,” Executive Editor Heather Landi chats with Rock Health’s Megan Zweig to talk about the state of the digital health market, how startups and investors are taking a different approach to dealmaking and what to expect for the rest of the year. |
|
|---|
|
|
|
Implementing effective corrective and preventive actions (CAPAs) to address rejects is essential to meeting regulatory requirements and to improving the manufacturing of sterile dosage forms going forward. This report examines the causes of high reject rates in sterile dosage manufacturing and describes how biopharmaceutical developers and CDMOs can work together to develop a strong CAPA strategy. Download now.
|
|
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
